KalVista Pharmaceuticals develops orally-delivered small molecule medicines, focusing on providing treatments for hereditary angioedema (HAE).

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. Common Stock

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. | 7,687 followers on LinkedIn. Creating a new generation of small molecule protease inhibitors for HAE and DME. | KalVista Pharmaceuticals is a biopharmaceutical company developing oral medicines designed to empower people to enjoy everyday life beyond the challenge of their disease. We apply our expertise to discover, develop and commercialize oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with sebetralstat, our first investigational product for hereditary angioedema (HAE), a rare genetic disease with debilitating attacks of tissue swelling that can be life threatening.

Manny Gaspar

Executive Director, Human Resources at KalVista Pharmaceuticals, Inc.

Kerrie Cutting

Peter Mutch

Executive Director, Head of Patient Services

Rachel Stay

Hear #KalVista ’s own Nicole Sweeny and Michael Smith speak with Linda, a person living with #HAE , about how our innovations are driven by the unmet needs of the HAE community.

#TeamKalVista had a successful #ACAAI24 ! We appreciate having the opportunity to speak with so many of you and extend a special thank you to everyone who attended our symposium focused on how physicians can address on-demand treatment behavior with their patients. See more of the work we shared: https://bit.ly/4hCmnHY .

Courage and compassion are at the heart of everything we do. Our courage drives us to innovate and push the boundaries of science, and our compassion reminds us that every patient, family, and community deserves the hope of new treatment options. If these values resonate, apply today to join #TeamKalVista : https://bit.ly/3NMR5R2 .

#TeamKalVista is here at #ACAAI24 ! Be sure to stop by booth #101 to learn more about how we’re advancing science to address the unmet need in #HAE . Also, don’t miss our symposium featuring Douglas Jones MD and Autumn Burnette on Sunday morning in Exhibit Halls C & D as well as our E-posters!

This past Saturday, members of #TeamKalVista joined the US Hereditary Angioedema Association (HAEA) in Chicago for an inspiring day of building #HAE awareness, making connections, and getting our steps in at the 2024 HAE IN-MOTION® awareness walk. Thank you to everyone who joined us!

Heading to #ACAAI24 ? So is #TeamKalVista ! Remember to visit booth #101 to meet with the team and learn more about our novel, scientific approach to tackling the unmet need in #HAE . We’re excited to see you there!

#TeamKalVista is thrilled to be a sponsor and participant at #ACAAI24 , hosted on October 24–28 in our backyard of Boston! From our booth and E-poster “Meet the Author” presentations to our symposium, we’ll be engaging with attendees all weekend long. Check out the E-poster schedule: https://bit.ly/3YbT7Pp

Learning to live with #HAE means being prepared to treat an attack at all times. Hear from Christina, a person living with HAE, for a firsthand account of the effects of delaying treatment.

Patients may delay treating #HAE with on-demand injectables due to fear of needles, avoiding pain from treatment, and lack of privacy to perform an injection. On-demand treatment options that are noninvasive have the potential to help patients better follow the recommended treatment guidelines. (Source: Valerieva A, Jones D, van Kooten S, Malloy N, Heckmann M, Betschel S. Treatment of HAE attacks with anticipated future oral on-demand therapies as reported by patients. Abstract presented at: EAACI Annual Meeting, May 31-June 3, 2024. Valencia, Spain. Allergy. In Press.)

On World Mental Health Day, we’re reminded that, for patients, anxiety often goes hand in hand with #HAE and its treatment. Having an attack management plan can help them feel prepared and make a difference in their wellbeing. Learn more about how you can support your patients’ needs: https://bit.ly/4f23cFn .

COM:KALVISTA

KalVista Pharmaceuticals

Last Close

9.32

22/11 21:00

Market Cap

530.31M

Beta: -

Volume Today

405.00K

Avg: -

name

homepage url

country

employee count

sector

industry

investor of

competitor of

Metrics